Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plexin-B2 (PLXNB2) is a type I transmembrane glycoprotein that functions as a cell surface receptor primarily for class 4 semaphorins and angiogenin (ANG). It plays critical roles in cell-cell signaling, axon guidance, cell migration, and cytoskeletal reorganization. PLXNB2 is involved in various cellular processes, including brain development, angiogenesis, and immune responses, making it a potential therapeutic target for cancer, neurodegenerative diseases, and hematopoietic disorders. Targeting the ANG-PLXNB2 axis has shown promise in preclinical studies.
The mechanism of action for drugs targeting PLXNB2 typically involves blocking the binding of its ligands (e.g., SEMA4C, Angiogenin) or disrupting its downstream signaling pathways (e.g., RHOA, AKT/ERK).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plexin-B2 (PLXNB2).